U
Aridis Pharmaceuticals, Inc.
ARDS
$0.0001
$0.000.00%
D
Sell
12/2/2024Upgraded
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D- from E+ on 12/2/2024 due to a noticeable increase in the volatility index.
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D- from E+ on 12/2/2024 due to a noticeable increase in the volatility index.
E
Sell
11/12/2024Downgrade
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E+ from D- on 11/12/2024 due to a noticeable decline in the volatility index.
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E+ from D- on 11/12/2024 due to a noticeable decline in the volatility index.
D
Sell
10/10/2024Upgraded
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D- from E+ on 10/10/2024 due to a substantial increase in the valuation index and volatility index.
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D- from E+ on 10/10/2024 due to a substantial increase in the valuation index and volatility index.
E
Sell
6/20/2024Upgraded
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to E+ from E on 6/20/2024 due to an increase in the volatility index and total return index.
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to E+ from E on 6/20/2024 due to an increase in the volatility index and total return index.
E
Sell
6/4/2024Downgrade
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E from E+ on 6/4/2024 due to a large decline in the growth index, volatility index and solvency index. EBIT declined 106.36% from $13.67M to -$869, earnings per share declined from $0.33 to -$0.0022, and total revenue declined 97.88% from $19.65M to $417.
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E from E+ on 6/4/2024 due to a large decline in the growth index, volatility index and solvency index. EBIT declined 106.36% from $13.67M to -$869, earnings per share declined from $0.33 to -$0.0022, and total revenue declined 97.88% from $19.65M to $417.
E
Sell
3/14/2023Downgrade
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index.
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E+ from D on 3/14/2023 due to a decline in the total return index.
D
Sell
2/9/2023Upgraded
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E+ from D on 2/8/2023 due to a decline in the volatility index.
D
Sell
11/22/2022Upgraded
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from D- on 11/22/2022 due to a substantial increase in the growth index and volatility index. Total revenue increased 36.64% from $292 to $399, operating cash flow increased 30.53% from -$6.14M to -$4.27M, and EBIT increased 4.2% from -$7.74M to -$7.41M.
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from D- on 11/22/2022 due to a substantial increase in the growth index and volatility index. Total revenue increased 36.64% from $292 to $399, operating cash flow increased 30.53% from -$6.14M to -$4.27M, and EBIT increased 4.2% from -$7.74M to -$7.41M.
D
Sell
8/17/2022Downgrade
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to D- from D on 8/17/2022 due to a major decline in the solvency index, growth index and volatility index. Total revenue declined 75.4% from $1.19M to $292, the quick ratio declined from 0.42 to 0.25, and debt to equity increased from -0.55 to -0.41.
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to D- from D on 8/17/2022 due to a major decline in the solvency index, growth index and volatility index. Total revenue declined 75.4% from $1.19M to $292, the quick ratio declined from 0.42 to 0.25, and debt to equity increased from -0.55 to -0.41.
D
Sell
8/9/2022Upgraded
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from D- on 8/9/2022 due to an increase in the volatility index and total return index.
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from D- on 8/9/2022 due to an increase in the volatility index and total return index.
D
Sell
7/25/2022Downgrade
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to D- from D on 7/25/2022 due to a decline in the volatility index and total return index.
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to D- from D on 7/25/2022 due to a decline in the volatility index and total return index.
D
Sell
7/8/2022Upgraded
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from D- on 7/8/2022 due to an increase in the volatility index.
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from D- on 7/8/2022 due to an increase in the volatility index.
D
Sell
6/17/2022Downgrade
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to D- from D on 6/17/2022 due to a decline in the volatility index.
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to D- from D on 6/17/2022 due to a decline in the volatility index.
D
Sell
6/2/2022Upgraded
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from D- on 6/2/2022 due to an increase in the volatility index.
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from D- on 6/2/2022 due to an increase in the volatility index.
D
Sell
5/18/2022Downgrade
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to D- from D on 5/18/2022 due to a decline in the volatility index and solvency index. The quick ratio declined from 0.55 to 0.42.
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to D- from D on 5/18/2022 due to a decline in the volatility index and solvency index. The quick ratio declined from 0.55 to 0.42.
D
Sell
5/17/2022Upgraded
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from E+ on 5/17/2022 due to an increase in the volatility index.
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from E+ on 5/17/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
D
Sell
5/6/2022Upgraded
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from E+ on 5/6/2022 due to an increase in the volatility index.
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from E+ on 5/6/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/26/2022Upgraded
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from E+ on 4/26/2022 due to an increase in the volatility index.
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from E+ on 4/26/2022 due to an increase in the volatility index.
E
Sell
4/20/2022Downgrade
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index.
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E+ from D on 4/20/2022 due to a decline in the volatility index.
D
Sell
4/19/2022Upgraded
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from D- on 4/19/2022 due to a noticeable increase in the growth index, solvency index and volatility index. Total revenue increased 91.65% from $515 to $987, earnings per share increased from -$1.9386 to -$0.6076, and EBIT increased 59.33% from -$21.03M to -$8.55M.
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from D- on 4/19/2022 due to a noticeable increase in the growth index, solvency index and volatility index. Total revenue increased 91.65% from $515 to $987, earnings per share increased from -$1.9386 to -$0.6076, and EBIT increased 59.33% from -$21.03M to -$8.55M.
D
Sell
11/11/2021Downgrade
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to D- from D on 11/11/2021 due to a large decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.4887 to -$1.94, EBIT declined 237.28% from -$6.23M to -$21.03M, and operating cash flow declined 30.06% from -$6.61M to -$8.59M.
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to D- from D on 11/11/2021 due to a large decline in the growth index, volatility index and total return index. Earnings per share declined from -$0.4887 to -$1.94, EBIT declined 237.28% from -$6.23M to -$21.03M, and operating cash flow declined 30.06% from -$6.61M to -$8.59M.
D
Sell
11/9/2021Upgraded
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index.
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index.
E
Sell
11/8/2021Downgrade
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E+ from D on 11/8/2021 due to a decline in the total return index, solvency index and volatility index. Debt to equity increased from -0.08 to 0, and the quick ratio declined from 0.44 to 0.16.
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E+ from D on 11/8/2021 due to a decline in the total return index, solvency index and volatility index. Debt to equity increased from -0.08 to 0, and the quick ratio declined from 0.44 to 0.16.
D
Sell
5/20/2020Upgraded
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from D- on 5/20/2020 due to an increase in the valuation index, total return index and volatility index.
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D from D- on 5/20/2020 due to an increase in the valuation index, total return index and volatility index.
D
Sell
3/16/2020Upgraded
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D- from E+ on 3/16/2020 due to an increase in the total return index and volatility index.
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D- from E+ on 3/16/2020 due to an increase in the total return index and volatility index.
E
Sell
2/27/2020Downgrade
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E+ from D- on 2/27/2020 due to a decline in the volatility index.
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E+ from D- on 2/27/2020 due to a decline in the volatility index.
D
Sell
2/11/2020Upgraded
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D- from E+ on 2/11/2020 due to an increase in the growth index, total return index and volatility index.
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D- from E+ on 2/11/2020 due to an increase in the growth index, total return index and volatility index.
E
Sell
1/27/2020Downgrade
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E+ from D- on 1/27/2020 due to a decline in the valuation index, growth index and total return index.
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E+ from D- on 1/27/2020 due to a decline in the valuation index, growth index and total return index.
D
Sell
12/17/2019Upgraded
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D- from E+ on 12/17/2019 due to an increase in the volatility index and valuation index.
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D- from E+ on 12/17/2019 due to an increase in the volatility index and valuation index.
E
Sell
12/2/2019Downgrade
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E+ from D- on 12/2/2019 due to a major decline in the solvency index, growth index and valuation index.
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E+ from D- on 12/2/2019 due to a major decline in the solvency index, growth index and valuation index.
D
Sell
5/1/2019Upgraded
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D- from E on 5/1/2019 due to an increase in the growth index, solvency index and volatility index. Earnings per share increased from -$1.97 to -$0.6711, total revenue increased 36.01% from $1.02M to $1.39M, and EBIT increased 15.76% from -$6.62M to -$5.58M.
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to D- from E on 5/1/2019 due to an increase in the growth index, solvency index and volatility index. Earnings per share increased from -$1.97 to -$0.6711, total revenue increased 36.01% from $1.02M to $1.39M, and EBIT increased 15.76% from -$6.62M to -$5.58M.
E
Sell
2/1/2019Upgraded
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to E from E- on 02/01/2019.
Aridis Pharmaceuticals, Inc. (ARDS) was upgraded to E from E- on 02/01/2019.
E
Sell
11/30/2018Downgrade
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E- from E on 11/30/2018 due to a noticeable decline in the volatility index.
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E- from E on 11/30/2018 due to a noticeable decline in the volatility index.
E
Sell
11/6/2018None
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E from U on 11/06/2018.
Aridis Pharmaceuticals, Inc. (ARDS) was downgraded to E from U on 11/06/2018.
OTC PK
04/11/2025 1:18PM Eastern
Quotes delayed
